计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| D413781-5mg |
5mg |
现货 ![]() |
| |
| D413781-25mg |
25mg |
现货 ![]() |
| |
| D413781-100mg |
100mg |
现货 ![]() |
|
| 别名 | 多马汀 (4SC-202) |
|---|---|
| 英文别名 | DB13101 | DOMATINOSTAT [WHO-DD] | HY-16012A | 4SC202 | 4SC-202 | 4SC-202 (free base) | AS-77606 | A860619 | C3202 | DOMATINOSTAT [INN] | CCG-269205 | SCHEMBL1613943 | 264ARM7UXX | Q27254045 | (E)-N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl |
| 规格或纯度 | ≥97% |
| 英文名称 | Domatinostat (4SC-202) |
| 生化机理 | 多马替司他 (4SC-202) 是一种选择性 I 类 HDAC 抑制剂,对 HDAC1、HDAC2 和 HDAC3 的 IC50 分别为 1.20 μM、1.12 μM 和 0.57 μM。对赖氨酸特异性去甲基化酶 1 (LSD1) 也有抑制活性。第 1 阶段 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
Information Domatinostat (4SC-202) is a selective class IHDACinhibitor withIC50of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity againstLysine specific demethylase 1 (LSD1). Phase 1. Targets HDAC3 (Cell-free assay); HDAC2 (Cell-free assay); HDAC1 (Cell-free assay); HDAC11 (Cell-free assay); HDAC5 (Cell-free assay) 15602,0.57 μM; 1.12 μM; 1.20 μM; 9.7 μM; 11.3 μM In vitro In HeLa cells, 4SC-202 induces hyperacetylation of histone H3 with EC50 of 1.1 μM. 4SC-202 induces a G2/M cell cycle arrest by interfering with the normal development of the mitotic spindle and causing collapsed spindle apparatus and multiple nucleation centres. In addition, 4SC-202 shows a broad anti-proliferative activity towards human cancer cell lines with a mean IC50 of 0.7 μM. In vivo 4SC-202 has a high oral bioavailability, and shows high metabolic stability and a low plasma clearance. 4SC-202 (120 mg/kg p.o.) shows pronounced and robust anti-tumor activity in both A549 NSCLC xenograft and RKO27 colon carcinoma model. Cell Research(from reference) Cell lines:CRC lines (HT-29, HCT-116, HT-15, and DLD-1) Concentrations:0.1, 1, 5, 10 μM Incubation Time:72 hours |
| 纯度 | ≥97% |
| IC50 | HDAC3, IC50: 0.57 μM |
|---|---|
| ALogP | 2.955 |
| hba_count | 4 |
| HBD Count | 2 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504767996 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (E)-N-(2-aminophenyl)-3-[1-[4-(1-methylpyrazol-4-yl)phenyl]sulfonylpyrrol-3-yl]prop-2-enamide |
| INCHI | 1S/C23H21N5O3S/c1-27-16-19(14-25-27)18-7-9-20(10-8-18)32(30,31)28-13-12-17(15-28)6-11-23(29)26-22-5-3-2-4-21(22)24/h2-16H,24H2,1H3,(H,26,29)/b11-6+ |
| InChi Key | PRXXYMVLYKJITB-IZZDOVSWSA-N |
| Smiles | CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)C=CC(=O)NC4=CC=CC=C4N |
| Isomeric SMILES | CN1C=C(C=N1)C2=CC=C(C=C2)S(=O)(=O)N3C=CC(=C3)/C=C/C(=O)NC4=CC=CC=C4N |
| 分子量 | 447.51 |
| Reaxy-Rn | 31334496 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=31334496&ln= |
| 溶解性 | Solubility (25°C) In vitro DMSO: 89 mg/mL (198.87 mM); Water: Insoluble; Ethanol: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 89 |
| DMSO(mM) Max Solubility | 198.8782374 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 447.500 g/mol |
| XLogP3 | 2.400 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 447.137 Da |
| 单同位素质量Monoisotopic Mass | 447.137 Da |
| 拓扑极表面积Topological Polar Surface Area | 120.000 Ų |
| 重原子数Heavy Atom Count | 32 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 775.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |